Galena Biopharma (GALE) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Roth Cap Remains Positive on Galena Biopharma (GALE) Following Q3 Results, Update
November 4, 2014 11:56 AM ESTRoth Capital affirms Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $8 following Q3 results.
Analyst Joseph Pantginis noted that Galena's loss of $0.05 per share compared with the firm's loss estimate of $0.18 per share and the consensus loss of $0.11 per share. The analyst noted that, Revenue, based on Abstral sales came in at $1.62 million compared with our estimate of $2.34 million and the consensus estimate of $2.66 million and the company reiterated... More
